-
-
-
-
-
-
-
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
-
-
-
-
-
-
-
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
-
-
-
-
-
-
-
GRI Bio Announces Closing of $8.0 Million Public Offering
-
-
-
-
-
-
-
GRI Bio reports interim biomarker data from phase 2a IPF study
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Announces Pricing of $5.0 Million Public Offering
-
-
-
-
-
-
-
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
-
1,185,844 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

